NASDAQ:NTRP - Neurotrope Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Neurotrope Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.17 -0.01 (-0.85 %) (As of 01/29/2020 08:00 AM ET) Add Compare Today's Range$1.12Now: $1.17▼$1.2050-Day Range$0.78MA: $1.04▼$1.4552-Week Range$0.63Now: $1.17▼$8.40Volume272,600 shsAverage Volume2.88 million shsMarket Capitalization$15.29 millionP/E RatioN/ADividend YieldN/ABeta1.98 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Neurotrope, Inc, a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NTRP Previous Symbol CUSIPN/A CIK1513856 Webhttp://www.neurotropebioscience.com/ Phone973-242-0005Debt Debt-to-Equity RatioN/A Current Ratio25.33 Quick Ratio25.33Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.05 per share Price / Book0.57Profitability EPS (Most Recent Fiscal Year)($1.37) Net Income$-11,020,000.00 Net MarginsN/A Return on Equity-72.04% Return on Assets-67.80%Miscellaneous Employees6 Outstanding Shares13,070,000Market Cap$15.29 million Next Earnings Date3/9/2020 (Estimated) OptionableOptionable Receive NTRP News and Ratings via Email Sign-up to receive the latest news and ratings for NTRP and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:NTRP Rates by TradingView Neurotrope (NASDAQ:NTRP) Frequently Asked Questions What is Neurotrope's stock symbol? Neurotrope trades on the NASDAQ under the ticker symbol "NTRP." How were Neurotrope's earnings last quarter? Neurotrope Inc (NASDAQ:NTRP) released its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.32) by $0.03. View Neurotrope's Earnings History. When is Neurotrope's next earnings date? Neurotrope is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Neurotrope. What price target have analysts set for NTRP? 2 brokerages have issued 1 year price objectives for Neurotrope's stock. Their forecasts range from $1.00 to $16.00. On average, they expect Neurotrope's share price to reach $8.50 in the next twelve months. This suggests a possible upside of 626.5% from the stock's current price. View Analyst Price Targets for Neurotrope. What is the consensus analysts' recommendation for Neurotrope? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurotrope in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Neurotrope. What are Wall Street analysts saying about Neurotrope stock? Here are some recent quotes from research analysts about Neurotrope stock: 1. According to Zacks Investment Research, "Neurotrope, Inc. is focused primarily on the development and commercialization of Alzheimer's disease therapeutic products related diagnostics. The Company develops and markets two product platforms, including a non-invasive diagnostic test for Alzheimer's disease and a drug candidate called bryostatin for the treatment of Alzheimer's disease, both of which are in the clinical testing stage. Neurotrope, Inc. is based in Plantation, Florida. " (11/1/2019) 2. Maxim Group analysts commented, "Neurotrope announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the development of Bryostatin-1 in acute lymphoblastic leukemia (ALL)." (2/5/2019) Has Neurotrope been receiving favorable news coverage? News stories about NTRP stock have been trending somewhat positive recently, InfoTrie Sentiment reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Neurotrope earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 8.0 out of 10, indicating that recent news coverage is very likely to have an effect on the company's share price in the next few days. View News Stories for Neurotrope. Are investors shorting Neurotrope? Neurotrope saw a decline in short interest during the month of December. As of December 31st, there was short interest totalling 536,700 shares, a decline of 7.6% from the December 15th total of 580,600 shares. Based on an average daily volume of 272,500 shares, the days-to-cover ratio is presently 2.0 days. Currently, 5.5% of the shares of the company are short sold. View Neurotrope's Current Options Chain. Who are some of Neurotrope's key competitors? Some companies that are related to Neurotrope include Aclaris Therapeutics (ACRS), Entasis Therapeutics (ETTX), Soligenix (SNGX), Alpine Immune Sciences (ALPN), Sunesis Pharmaceuticals (SNSS), Acasti Pharma (ACST), Kezar Life Sciences (KZR), American Brivision (Holding) (ABVC), SCYNEXIS (SCYX), Vascular Biogenics (VBLT), Onconova Therapeutics (ONTX), resTORbio (TORC), SUMMIT THERAPEU/S (SMMT), DiaMedica Therapeutics (DMAC) and Hoth Therapeutics (HOTH). What other stocks do shareholders of Neurotrope own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neurotrope investors own include Sarepta Therapeutics (SRPT), Fibrocell Science (FCSC), Neos Therapeutics (NEOS), Alibaba Group (BABA), Pieris Pharmaceuticals (PIRS), Canopy Growth (CGC), Innovate Biopharmaceuticals (INNT), Intel (INTC), Iovance Biotherapeutics (IOVA) and Adamis Pharmaceuticals (ADMP). Who are Neurotrope's key executives? Neurotrope's management team includes the folowing people: Dr. Charles S. Ryan, CEO & Director (Age 55)Dr. Daniel L. Alkon, Pres & Chief Scientific Officer (Age 77)Mr. Robert Weinstein, CFO, Exec. VP, Sec. & Treasurer (Age 59)Dr. Michael Ciraolo, Gen. Counsel & COO (Age 46)Mr. Jeffrey Benison, Director of Corp. Communications How do I buy shares of Neurotrope? Shares of NTRP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Neurotrope's stock price today? One share of NTRP stock can currently be purchased for approximately $1.17. How big of a company is Neurotrope? Neurotrope has a market capitalization of $15.29 million. The company earns $-11,020,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis. Neurotrope employs 6 workers across the globe.View Additional Information About Neurotrope. What is Neurotrope's official website? The official website for Neurotrope is http://www.neurotropebioscience.com/. How can I contact Neurotrope? Neurotrope's mailing address is 1185 AVENUE OF THE AMERICAS 3RD FLOOR, NEW YORK NY, 10036. The company can be reached via phone at 973-242-0005 or via email at [email protected] MarketBeat Community Rating for Neurotrope (NASDAQ NTRP)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 170 (Vote Outperform)Underperform Votes: 200 (Vote Underperform)Total Votes: 370MarketBeat's community ratings are surveys of what our community members think about Neurotrope and other stocks. Vote "Outperform" if you believe NTRP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTRP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/29/2020 by MarketBeat.com StaffFeatured Article: If I purchase shares through a brokerage account, am I the holder of record?
